ODDB.org: Open Drug Database | Medikamente

Sie befinden sich in -

Home

Fachinformation zu Nulojix®

Fachinformation zu Nulojix®:

Bristol-Myers Squibb SA

L04AA28 - Belatacept

ATC-DDD Version 2012. Source: WHO

L - Antineoplastic and Immunomodulating Agents

This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.

L04 - Immunosuppressants

Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.

L04A - Immunosuppressants

This group comprises immunosuppressants excl. corticosteroids.

The DDDs are mainly based on prophylaxis of allograft transplant rejection.
The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.
The DDD for efalizumab is based on the treatment of plaque psoriasis.
The DDDs for etanercept, infliximab, leflunomide, anakinra and adalimumab are based on the treatment of rheumatoid arthritis.
The DDD for thalidomide is based on the treatment of erythema nodosum leprosum.
The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.

L04AA - Selective Immunosuppressants

Antilymphocyte immunoglobulin from horse serum is classified in L04AA03.
Antithymocyte immunoglobulin from rabbit serum is classified in L04AA04.

L04AA28 - Belatacept

2013